Cat. No：GM-C30928
Product：H_EGFR(L747S-T790M-C797S) BAF3 Cell Line
Cat. No：GM-C30928
Product：H_EGFR(L747S-T790M-C797S) BAF3 Cell Line
Cell Growth Medium: RPMI 1640+10% FBS+1% P.S+0.25 μg/mL Puromycin
Cell Freezing Medium: 90% FBS+10% DMSO
Assay Buffer: RPMI 1640+10% FBS+1% P.S
EGFR is a member of the receptor tyrosine kinase (TK) family. It is widely distributed on the surface of mammalian fibroblasts, epithelial cells, and other cell types. The EGFR signaling pathway plays a crucial role in various physiological processes, including cell proliferation and differentiation. When mutations occur in EGFR, it leads to the continuous activation of the EGFR signaling pathway without ligand binding, resulting in abnormal cell proliferation. EGFR mutations have been found in various tumors, such as non-small cell lung cancer, breast cancer, colorectal cancer, and head and neck squamous cell carcinoma (HNSCC). There are several tyrosine kinase inhibitors (TKIs) targeting EGFR mutations, including Afatinib, Erlotinib, Gefitinib, Osimertinib (AZD 9291), and Cetuximab. BA/F3 cells are interleukin-3 (IL-3) dependent precursor B cells, and some protein kinases can substitute for IL-3 to enable the growth of BA/F3 cells; this function can then be antagonized using inhibitors, making it valuable for kinase inhibitor research.
Cat. No：GM-C30928
Product：H_EGFR(L747S-T790M-C797S) BAF3 Cell Line
Cell Growth Medium: RPMI 1640+10% FBS+1% P.S+0.25 μg/mL Puromycin
Cell Freezing Medium: 90% FBS+10% DMSO
Assay Buffer: RPMI 1640+10% FBS+1% P.S
EGFR is a member of the receptor tyrosine kinase (TK) family. It is widely distributed on the surface of mammalian fibroblasts, epithelial cells, and other cell types. The EGFR signaling pathway plays a crucial role in various physiological processes, including cell proliferation and differentiation. When mutations occur in EGFR, it leads to the continuous activation of the EGFR signaling pathway without ligand binding, resulting in abnormal cell proliferation. EGFR mutations have been found in various tumors, such as non-small cell lung cancer, breast cancer, colorectal cancer, and head and neck squamous cell carcinoma (HNSCC). There are several tyrosine kinase inhibitors (TKIs) targeting EGFR mutations, including Afatinib, Erlotinib, Gefitinib, Osimertinib (AZD 9291), and Cetuximab. BA/F3 cells are interleukin-3 (IL-3) dependent precursor B cells, and some protein kinases can substitute for IL-3 to enable the growth of BA/F3 cells; this function can then be antagonized using inhibitors, making it valuable for kinase inhibitor research.
